Cargando…

Retinal thickness as a potential biomarker in patients with amyloid-proven early- and late-onset Alzheimer's disease

INTRODUCTION: Retinal thickness measured with optical coherence tomography has been proposed as a noninvasive biomarker for Alzheimer's disease (AD). We therefore measured retinal thickness in well-characterized AD and control participants, considering ophthalmological confounders. METHODS: We...

Descripción completa

Detalles Bibliográficos
Autores principales:	den Haan, Jurre, van de Kreeke, Jacoba A., Konijnenberg, Elles, ten Kate, Mara, den Braber, Anouk, Barkhof, Frederik, van Berckel, Bart N., Teunissen, Charlotte E., Scheltens, Philip, Visser, Pieter Jelle, Verbraak, Frank D., Bouwman, Femke H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2019
Materias:	Retinal Imaging
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6584766/ https://www.ncbi.nlm.nih.gov/pubmed/31249859 http://dx.doi.org/10.1016/j.dadm.2019.05.002

Ejemplares similares

Is retinal vasculature a biomarker in amyloid proven Alzheimer's disease?
por: den Haan, Jurre, et al.
Publicado: (2019)

Retinal thickness correlates with parietal cortical atrophy in early-onset Alzheimer's disease and controls
por: den Haan, Jurre, et al.
Publicado: (2017)

Retinal thickness in Alzheimer's disease: A systematic review and meta-analysis
por: den Haan, Jurre, et al.
Publicado: (2017)

Retinal layer thickness in preclinical Alzheimer's disease
por: van de Kreeke, Jacoba A., et al.
Publicado: (2019)

Optical coherence tomography angiography in preclinical Alzheimer’s disease
por: van de Kreeke, Jacoba Alida, et al.
Publicado: (2020)

No difference in retinal fluorescence after oral curcumin intake in amyloid‐proven AD cases compared to controls
por: den Haan, Jurre, et al.
Publicado: (2022)

Longitudinal retinal layer changes in preclinical Alzheimer’s disease
por: van de Kreeke, Jacoba A., et al.
Publicado: (2020)

Ocular biomarkers for cognitive impairment in nonagenarians; a prospective cross-sectional study
por: van de Kreeke, Jacoba A., et al.
Publicado: (2020)

The EMIF-AD PreclinAD study: study design and baseline cohort overview
por: Konijnenberg, Elles, et al.
Publicado: (2018)

Amyloid-driven disruption of default mode network connectivity in cognitively healthy individuals
por: Ingala, Silvia, et al.
Publicado: (2021)

Associations of Brain Pathology Cognitive and Physical Markers With Age in Cognitively Normal Individuals Aged 60–102 Years
por: Legdeur, Nienke, et al.
Publicado: (2019)

Assessing Amyloid Pathology in Cognitively Normal Subjects Using (18)F-Flutemetamol PET: Comparing Visual Reads and Quantitative Methods
por: Collij, Lyduine E., et al.
Publicado: (2019)

Onset of Preclinical Alzheimer Disease in Monozygotic Twins
por: Konijnenberg, Elles, et al.
Publicado: (2021)

White matter microstructure disruption in early stage amyloid pathology
por: Collij, Lyduine E., et al.
Publicado: (2021)

Abnormal cerebrospinal fluid levels of amyloid and tau are associated with cognitive decline over time in cognitively normal older adults: A monozygotic twin study
por: Tomassen, Jori, et al.
Publicado: (2022)

Detecting signs of retinal leakage in exudative AMD using Cirrus OCT versus SL SCAN-1, a novel integrated FD-OCT into a common slit lamp
por: Stehouwer, M., et al.
Publicado: (2015)

Plasma biomarkers predict amyloid pathology in cognitively normal monozygotic twins after 10 years
por: den Braber, Anouk, et al.
Publicado: (2023)

Amyloid-independent atrophy patterns predict time to progression to dementia in mild cognitive impairment
por: ten Kate, Mara, et al.
Publicado: (2017)

Amyloid-beta and phosphorylated tau in post-mortem Alzheimer’s disease retinas
por: den Haan, Jurre, et al.
Publicado: (2018)

Amyloid-β and APOE genotype predict memory decline in cognitively unimpaired older individuals independently of Alzheimer’s disease polygenic risk score
por: Tomassen, Jori, et al.
Publicado: (2022)

Why Is Amyloid-β PET Requested After Performing CSF Biomarkers?
por: Reimand, Juhan, et al.
Publicado: (2020)

Genetically identical twins show comparable tau PET load and spatial distribution
por: Coomans, Emma M, et al.
Publicado: (2022)

Diagnostic impact of [(18)F]flutemetamol PET in early-onset dementia
por: Zwan, Marissa D., et al.
Publicado: (2017)

PET and CSF amyloid-β status are differently predicted by patient features: information from discordant cases
por: Reimand, Juhan, et al.
Publicado: (2019)

Genetically identical twin-pair difference models support the amyloid cascade hypothesis
por: Coomans, Emma M, et al.
Publicado: (2023)

Amyloid‐β, cortical thickness, and subsequent cognitive decline in cognitively normal oldest‐old
por: Pelkmans, Wiesje, et al.
Publicado: (2021)

ATN classification and clinical progression in subjective cognitive decline: The SCIENCe project
por: Ebenau, Jarith L., et al.
Publicado: (2020)

α-Synuclein pathology in post-mortem retina and optic nerve is specific for α-synucleinopathies
por: Hart de Ruyter, Frederique J., et al.
Publicado: (2023)

Different curcumin forms selectively bind fibrillar amyloid beta in post mortem Alzheimer’s disease brains: Implications for in-vivo diagnostics
por: den Haan, Jurre, et al.
Publicado: (2018)

Retinal thickness as potential biomarker in posterior cortical atrophy and typical Alzheimer’s disease
por: den Haan, Jurre, et al.
Publicado: (2019)

Performance of a [(18)F]Flortaucipir PET Visual Read Method Across the Alzheimer Disease Continuum and in Dementia With Lewy Bodies
por: Coomans, Emma M., et al.
Publicado: (2023)

Clinical characteristics of chronic central serous chorioretinopathy patients with insufficient response to reduced-settings photodynamic therapy
por: van Rijssen, Thomas J., et al.
Publicado: (2018)

Genetic, vascular and amyloid components of cerebral blood flow in a preclinical population
por: Padrela, Beatriz E, et al.
Publicado: (2023)

Prospective evaluation of changes in choroidal vascularity index after half-dose photodynamic therapy versus micropulse laser treatment in chronic central serous chorioretinopathy
por: van Rijssen, Thomas J., et al.
Publicado: (2020)

Outcome of half-dose photodynamic therapy in chronic central serous chorioretinopathy with fovea-involving atrophy
por: van Rijssen, Thomas J., et al.
Publicado: (2020)

Long-term follow-up of chronic central serous chorioretinopathy patients after primary treatment of oral eplerenone or half-dose photodynamic therapy and crossover treatment: SPECTRA trial report No. 3
por: Feenstra, Helena M. A., et al.
Publicado: (2022)

Design of the NL-ENIGMA study: Exploring the effect of Souvenaid on cerebral glucose metabolism in early Alzheimer's disease
por: Scheltens, Nienke M.E., et al.
Publicado: (2016)

Amyloid‐β PET and CSF in an autopsy‐confirmed cohort
por: Reimand, Juhan, et al.
Publicado: (2020)

The effect of a preoperative subconjuntival injection of dexamethasone on blood–retinal barrier breakdown following scleral buckling retinal detachment surgery: a prospective randomized placebo-controlled double blind clinical trial
por: Bali, Ernesto, et al.
Publicado: (2010)

Cost-minimisation analysis of a treat-and-extend regimen with anti-VEGFs in patients with neovascular age-related macular degeneration
por: Quist, S. W., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_q69e1penrefc2scor36pf275dk